MediciNova Provides Shareholder Update on Key Developments
1. MediciNova signed a SEPA for up to $30 million in common stock. 2. Successful enrollment in COMBAT-ALS trial for MN-166, promising for ALS treatment. 3. Plans to use proceeds for R&D and corporate activities. 4. MN-001 trial also progressing; potential for broader applications. 5. CEO emphasizes ongoing development and need for capital flexibility.